drugset / Trial / NCT00515320

Study of Fluoxetine in Autism

NCT00515320

Phase 3 Completed 158 enrolled Neuropharm Autism Speaks · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the effect of fluoxetine orally dissolving tablets (ODT) on the repetitive behaviors core domain in children and adolescents with Autistic Disorder. The study will also investigate the effect of fluoxetine on the improvement of symptoms and the effects on daily living of the patient's family.

Timeline

Start
2007-08
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 2 mg Oral
Subject Fluoxetine Small molecule 9 mg Oral
Subject Fluoxetine Small molecule 18 mg Oral